Myovant Sciences Ltd and Pfizer Inc MYFEMBREE FDA sNDA Approval Call Transcript
Good day, and thank you for standing by. Welcome to the MYFEMBREE FDA sNDA Approval Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Uneek Mehra, Chief Financial and Business Officer. Please go ahead.
Thank you, operator. Good morning, and thank you for joining us today to discuss the exciting news of the FDA approval of MYFEMBREE for the management of moderate-to-severe pain associated with endometriosis in pre-menopausal women. Our press release as well as the slides that will be presented during today's webcast will be available on our Investor Relations website, investors.myovant.com.
Joining me for today's call are Dave Marek, Myovant's Chief Executive Officer; Lauren Merendino, Chief Commercial Officer; and Dr. Juan Camilo Arjona, our Chief Medical Officer.
During this conference call, we will be making forward-looking statements. These
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |